Masafumi Kinoshita
Kobe, 6590021, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Translational applicability of human blood-brain barrier spheroid models for the development of brain-penetrant therapeutic antibodies.
Journal: Fluids and barriers of the CNS
Published: August 26, 2025
Adeno-associated virus expressing a blood-brain barrier-penetrating enzyme improves GM1 gangliosidosis in a preclinical model.
Journal: The Journal of clinical investigation
Published: March 04, 2024
Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.
Journal: International journal of molecular sciences
Published: September 07, 2022
Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II.
Journal: Molecular genetics and metabolism reports
Published: April 12, 2021
Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 16, 2020
Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Journal: Molecular genetics and metabolism
Published: March 07, 2018
A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 14, 2017
Orally administered phosphatidic acids and lysophosphatidic acids ameliorate aspirin-induced stomach mucosal injury in mice.
Journal: Digestive diseases and sciences
Published: July 01, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026